Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs

Biomaterials

Volumn 32, Issue 31, 2011, Pages 7924-7931

  Yuk, Soon Hong ^a   Oh, Keun Sang ^b   Koo, Heebeom ^b   Jeon, Hyesung ^b   Kim, Kwangmeyung ^b   Kwon, Ick Chan ^b  

^a Korea University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

Author keywords

Chemotherapy; Docetaxel; Drug delivery; Multi core vesicle nanoparticles; Pluronic

Indexed keywords

ANIMAL IMAGING; ANTICANCER DRUG; AQUEOUS MEDIUM; CIRCULATION TIME; CRYO-TEM; DELIVERY SYSTEMS; DOCETAXEL; IN-VIVO; MORPHOLOGY AND SIZE; MULTI CORE; NON-INVASIVE; PARTICLE SIZE ANALYZERS; PLURONICS; RELEASE PATTERN; TAIL VEINS; TIME-DEPENDENT; TUMOR GROWTH; TUMOR TARGETING; VESICLE FUSION;

CHEMOTHERAPY; DRUG DELIVERY; GLYCOLS; MAMMALS; PARTICLE SIZE ANALYSIS; POLYETHYLENE GLYCOLS; TUMORS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; DOCETAXEL; MACROGOL; MULTICORE VESICLE NANOPARTICLE; NANOPARTICLE; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG RELEASE; DRUG TARGETING; MALE; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYOELECTRON MICROSCOPY; DRUG DELIVERY SYSTEMS; MEMBRANE FUSION; MICE; NANOPARTICLES; PARTICLE SIZE; SPECTROSCOPY, NEAR-INFRARED; TAXOIDS; TREATMENT OUTCOME; UNILAMELLAR LIPOSOMES;

ANIMALIA; MUS;

EID: 80051817296     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.017     Document Type: Article

References (29)

1. Wang X., Li Y., Yao H., Ju R., Zhang Y., Li R., et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011, 32:5673-5687.
2. Dos Santos N., Waterhouse D., Masin D., Tardi P.G., Karlsson G., Edwards K., et al. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release 2005, 105:89-105.
3. Thomann J.S., Heurtault B., Weidner S., Brayé M., Beyrath J., Fournel S., et al. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011, 32:4574-4583.
4. Inoh Y., Kitamoto D., Hirashima N., Nakanishi M. Biosurfactant MEL-A dramatically increases gene transfection via membrane fusion. J Control Release 2004, 94:423-431.
5. Kono K., Nakashima S., Kokuryo D., Aoki I., Shimomoto H., Aoshima S., et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 2011, 32:1387-1395.
6. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996, 36:55-63.
7. Liu J., Jiang X., Ashley C., Brinker C.J. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J Am Chem Soc 2009, 131:7567-7569.
8. Lei G., MacDonald R.C. Lipid bilayer vesicle fusion: intermediates captured by high-speed microfluorescence spectroscopy. Biophys J 2003, 85:1585-1599.
9. Wang B., Zhang L., Bae S.C., Granick S. Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc Natl Acad Sci U S A 2008, 105:18171-18175.
10. Zhang L., Hong L., Yu Y., Bae S.C., Granick S. Nanoparticle-assisted surface immobilization of phospholipid liposomes. J Am Chem Soc 2006, 128:9026-9027.
11. Liu J., Stace-Naughton A., Jiang X., Brinker C.J. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc 2009, 131:1354-1355.
12. Smith K.A., Jasnow D., Balazs A.C. Designing synthetic vesicles that engulf nanoscopic particles. J Chem Phys 2007, 127. 084703-1-10.
13. Carr R., Weinstock I.A., Sivaprasadarao A., Müller A., Aksimentiev A. Synthetic ion channels via self-assembly: a route for embedding porous polyoxometalate nanocapsules in lipid bilayer membranes. Nano Lett 2008, 8:3916-3921.
14. Pornpattananangkul D., Olson S., Aryal S., Sartor M., Huang C., Vecchio K., et al. Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano 2010, 4:1935-1942.
15. Oh K.S., Song J.Y., Cho S.H., Lee B.S., Kim S.Y., Kim K., et al. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. J Control Release 2010, 148:344-350.
16. Yin Y.M., Cui F.D., Mu C.F., Choi M.K., Kim J.S., Chung S.J., et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009, 140:86-94.
17. Mu C.F., Balakrishnan P., Cui F.D., Yin Y.M., Lee Y.B., Choi H.G., et al. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010, 31:2371-2379.
18. Ferrandina G., Ludovisi M., De Vincenzo R., Salutari V., Lorusso D., Colangelo M., et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 2007, 18:1348-1353.
19. Twelves C. Docetaxel weekly with metastatic breast cancer. Onkologie 2007, 30:407-408.
20. Jiang Z., Yan W., Ming J., Yu Y. Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer 2007, 7:189-193.
21. Higuchi E., Oridate N., Homma A., Suzuki F., Atago Y., Nagahashi T., et al. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy. Head Neck 2007, 29:940-947.
22. Lavelle F., Bissery M.C., Combeau C., Riou J.F., Vrignaud P., André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995, 22:3-16.
23. Persohn E., Canta A., Schoepfer S., Traebert M., Mueller L., Gilardini A., et al. Morphological and morphometric analysis of paclitaxel and docetaxel induced peripheral neuropathy in rats. Eur J Cancer 2005, 41:1460-1466.
24. Baker J., Ajani J., Scotté F., Winther D., Martin M., Aapro M.S., et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009, 13:49-59.
25. Roché H., Fumoleau P., Spielmann M., Canon J.L., Delozier T., Serin D., et al. Sequential adjuvant epirubicin based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
26. Mi Y., Liu Y., Feng S.S. Formulation of Docetaxel by folic acid-conjugated D-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32:4058-4066.
27. Lu R.M., Chang Y.L., Chen M.S., Wu H.C. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32:3265-3274.
28. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
29. Kim J.H., Kim Y.S., Kim S., Park J.H., Kim K., Choi K., et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release 2006, 111:228-234.